Probiotics: Does It Actually Work?
Last reviewed: 2026-02-20 00:00:00 +0000 UTC
Meta-analysis verifiedSnakeOilCheck earns commissions from qualifying purchases made through affiliate links on this site. Our editorial content and meta-analyses are produced independently and are not influenced by affiliate relationships.
What Are Probiotics?
Probiotics are live bacteria and yeasts that you take as supplements. They’re meant to support the trillions of microbes already living in your gut. The idea is simple: add good bacteria, improve your health.
But here’s what most people get wrong. “Probiotics” isn’t one thing. It’s a category. Different strains do different things. Taking a random probiotic for depression is like taking a random antibiotic for a specific infection. The strain matters.
We looked at data from over 100 RCTs across three major meta-analyses. Here’s what the evidence actually supports.
The Evidence, Claim by Claim
The sections below break down each claim with real numbers from published meta-analyses. Every effect size, confidence interval, and study count comes from peer-reviewed research.
Gut Health and IBS: The Strongest Case
This is where probiotics shine. Chen et al. (2023) ran a three-level meta-analysis of 72 RCTs with 8,581 people. They found a moderate improvement in global IBS symptoms (SMD -0.55). That’s clinically meaningful.
Abdominal pain improved even more (SMD -0.89). Bacillus strains were the standout performers for pain relief.
A second massive analysis by Goodoory et al. (2023) looked at 82 RCTs with 10,332 people. They confirmed the finding: probiotics reduce the risk of persistent IBS symptoms (RR 0.79). L. plantarum 299V had the best individual strain data across 5 trials.
The catch? Heterogeneity is extremely high (I2 = 96.3%). That means results vary wildly between studies. Some people get huge benefits. Others don’t notice much. Strain choice matters, and we can’t predict who will respond best.
Respiratory Infections: Cochrane-Backed
A 2022 Cochrane review (the gold standard) looked at 24 RCTs with 6,950 people. Probiotics reduced the risk of getting at least one upper respiratory infection by 24% (RR 0.76).
The strongest finding: people taking probiotics were 41% less likely to get 3 or more infections per year (RR 0.59). This result had zero heterogeneity, meaning the studies agreed with each other. That’s rare and impressive.
Colds were about 1.2 days shorter. Antibiotic prescriptions dropped by 42%. These are practical benefits that matter in the real world.
Certainty was rated Low to Moderate. Not because the results are bad, but because the studies used different strains, doses, and populations.
Mood and Depression: Promising but Inconsistent
Asad et al. (2025) pooled 23 RCTs with 1,401 participants. They found a large effect on depression scores (SMD -0.96). Anxiety also improved (SMD -0.59).
Sounds great. But there are red flags.
Heterogeneity is high (I2 = 85%). The effect was much larger in people with clinical depression compared to healthy volunteers. And shorter studies showed bigger effects than longer ones. That’s not the pattern you want to see. It suggests the benefit might fade over time.
This claim gets a “maybe” verdict. The gut-brain axis is real. Probiotics probably do something for mood. But we need longer, more consistent trials before we can say it works with confidence.
Strain Specificity: The Most Important Thing to Know
Here’s the most important takeaway from this page. Not all probiotics are the same.
Saying “probiotics work for IBS” is like saying “drugs work for pain.” Which drug? Which dose? Which type of pain?
L. plantarum 299V has good IBS data. Bacillus strains are best for abdominal pain. Lactobacillus rhamnosus GG is well-studied for diarrhea. A random store-brand “probiotic blend” with no strain codes on the label? That’s a coin flip.
When you’re shopping, look for specific strain designations. Not just “Lactobacillus acidophilus,” but the full strain code. That’s where the research lives.
Dosage and How to Take Them
Most studies used between 1 billion and 100 billion CFU per day. The sweet spot for most people is 10-20 billion CFU of a multi-strain formula.
Don’t chase the highest CFU count. A well-studied strain at 10 billion CFU will beat a mystery strain at 200 billion. Quality over quantity.
Timing varies by strain. Some work better with food, others on an empty stomach. Check the label.
Give them 2-4 weeks for gut symptoms. Mood benefits (if they happen) take 4-8 weeks to show up.
No cycling is needed. Take them daily and consistently.
Some probiotics need refrigeration. Others are shelf-stable. Products with good encapsulation technology (enteric coating, triple encapsulation) can survive at room temperature just fine.
Who Should NOT Take Probiotics
Most healthy adults can take probiotics without any issues. They’re one of the safest supplement categories out there.
But don’t take them if you’re severely immunocompromised. This includes organ transplant recipients on immunosuppressant drugs, people undergoing chemotherapy, and patients with late-stage HIV. Live bacteria could cause bloodstream infections in people with very weak immune systems.
Avoid if you have short bowel syndrome or a central venous catheter.
If you’re taking antibiotics, separate your probiotic dose by 2-3 hours. Otherwise the antibiotic will just kill the probiotic bacteria.
Mild gas and bloating during the first few days is normal. It usually goes away within a week.
The Bottom Line
Probiotics work for gut health and IBS. That’s backed by massive meta-analyses with thousands of participants. They also reduce respiratory infections, which a Cochrane review confirmed.
The mood and depression data is exciting but not ready for a strong recommendation yet. High heterogeneity and the pattern of shorter-is-better raises questions.
The single most important thing to remember: strain specificity matters. Don’t buy generic “probiotic” bottles with vague labels. Look for products that list specific strain codes and have third-party testing for viability. Your gut bacteria are picky. The research says you should be too.
The Evidence, Claim by Claim
Improves IBS and gut health ✓ Works
72 studies with over 8,500 people found probiotics significantly improve IBS symptoms. The effect is moderate. Abdominal pain improves the most, especially with Bacillus strains. Quality of life also gets a meaningful boost.
Very high heterogeneity (I2 = 96.3%) is the big caveat. Different strains, doses, and populations produce wildly different results. The direction is consistent, but the size of the benefit varies a lot. Goodoory et al. (82 RCTs, 10,332 participants) confirmed the finding with RR 0.79.
View full statistical analysis
Publication Bias Assessment
| Egger's Test | z = —, p = 0.08 | some asymmetry detected but not statistically significant |
|---|
Subgroup Analysis
| Subgroup | Studies (k) | Effect (g) |
|---|---|---|
| Bacillus | 8 | -0.89 |
| Lactobacillus | 28 | -0.52 |
| Multi-strain | 22 | -0.48 |
| Bifidobacterium | 14 | -0.41 |
Reduces respiratory infections ✓ Works
A Cochrane review of 24 studies with nearly 7,000 people found probiotics reduce your chance of getting at least one upper respiratory infection by about 24%. People who took probiotics were also 41% less likely to get 3 or more infections. Colds were about 1.2 days shorter.
This is a Cochrane review, which is the gold standard. But certainty was rated Low for most outcomes because of high heterogeneity. The 3+ infections finding had Moderate certainty and zero heterogeneity, making it the strongest result. Antibiotic use dropped by 42%, which is clinically meaningful.
View full statistical analysis
Publication Bias Assessment
| Egger's Test | z = —, p = — | not formally assessed in Cochrane review |
|---|
Improves mood and depression ? Maybe
23 studies with about 1,400 people found a large effect of probiotics on depression scores. Anxiety scores also improved. The effect was bigger in people with clinical depression compared to healthy volunteers. Shorter trials showed larger effects, which raises some questions about durability.
The effect size (SMD -0.96) looks impressive, but I2 = 85% means results vary a lot between studies. The prediction interval crosses zero, so a new study might not find a benefit. Effects were larger in clinically depressed populations and in shorter trials. This needs more research, especially longer studies.
View full statistical analysis
Publication Bias Assessment
| Egger's Test | z = —, p = — | potential asymmetry, insufficient studies for robust testing |
|---|
Subgroup Analysis
| Subgroup | Studies (k) | Effect (g) |
|---|---|---|
| Clinically diagnosed | 12 | -1.22 |
| Healthy volunteers | 11 | -0.45 |
| Subgroup | Studies (k) | Effect (g) |
|---|---|---|
| <8 weeks | 10 | -1.15 |
| >=8 weeks | 13 | -0.72 |
Prevents antibiotic-associated diarrhea ✓ Works
42 studies with over 11,000 adults found probiotics reduce your risk of getting diarrhea from antibiotics by 37%. The benefit is strongest in people who are already at high risk for this side effect. You'd need to treat about 20 patients to prevent one case. Lactobacillus and Bifidobacterium strains are the most effective.
GRADE quality is Moderate. Three independent meta-analyses (Goodman 2021, Liao 2021, Hempel 2012) all found consistent 37-42% risk reductions. However, when restricted to low risk-of-bias studies only (k=6), the effect was no longer significant (RR 0.78, p=0.13). This is a real but possibly overstated effect. Baseline risk matters a lot.
View full statistical analysis
Publication Bias Assessment
| Egger's Test | z = —, p = — | funnel plot symmetrical, suggesting little evidence of publication bias |
|---|
Subgroup Analysis
| Subgroup | Studies (k) | Effect (g) |
|---|---|---|
| Lactobacillus spp | 28 | 0.63 |
| L. acidophilus | 18 | 0.66 |
| S. boulardii | 9 | 0.63 |
| L. casei | 11 | 0.59 |
| B. longum | 4 | 0.46 |
| Subgroup | Studies (k) | Effect (g) |
|---|---|---|
| High (>31%) | 14 | 0.55 |
| Moderate (11-30%) | 21 | 0.61 |
| Low (<11%) | 7 |
Prevents C. difficile-associated diarrhea ✓ Works
A Cochrane review of 31 trials with 8,672 people found probiotics cut the risk of C. difficile diarrhea by 60%. The incidence dropped from 4.0% in the control group to 1.5% in the probiotic group. In high-risk patients (baseline risk over 5%), the reduction was even bigger at 70%, with a number needed to treat of just 12.
This is Cochrane-quality evidence rated Moderate certainty. The 60% risk reduction is dramatic. But it only applies to people already at elevated risk. In low-risk populations (baseline CDAD under 2%), there was no significant benefit. Probiotics also reduced adverse events by 17%, so they're safe in this context. Probiotics may reduce diarrhea symptoms but don't prevent C. difficile colonization itself.
View full statistical analysis
Publication Bias Assessment
| Egger's Test | z = —, p = — | not formally tested, but sensitivity analyses robust to missing data assumptions |
|---|
Subgroup Analysis
| Subgroup | Studies (k) | Effect (g) |
|---|---|---|
| High (>5%) | 13 | 0.3 |
| Moderate (3-5%) | ||
| Low (0-2%) |
Reduces diarrhea duration in acute gastroenteritis ? Maybe
The evidence here is conflicting. A network meta-analysis of 84 studies with 13,443 children found S. boulardii shortens diarrhea by about 1.25 days. But a 2020 Cochrane review of 82 studies found no benefit when they only looked at the highest-quality trials. Two large, well-designed NEJM trials (nearly 1,800 children combined) found zero benefit from L. rhamnosus GG.
This claim gets a 'maybe' because the evidence is genuinely split. Multiple meta-analyses find a benefit (Li 2021 NMA, Yang 2019, Alsabri 2025), but the Cochrane 2020 review (Collinson et al.) concluded probiotics 'probably make little or no difference' based on low-bias studies. Publication bias is a proven concern. S. boulardii has the best strain-specific evidence. L. rhamnosus GG failed in the two largest placebo-controlled trials. The truth likely depends on the strain, the population, and the pathogen.
View full statistical analysis
Publication Bias Assessment
| Egger's Test | z = —, p = 0.002 | publication bias demonstrated in Cochrane review, funnel plots clearly asymmetric |
|---|
Subgroup Analysis
| Subgroup | Studies (k) | Effect (g) |
|---|---|---|
| S. boulardii | -1.25 | |
| L. acidophilus | -0.84 | |
| B. clausii | -0.98 |
Improves blood sugar control in type 2 diabetes ? Maybe
30 studies with 1,827 people with type 2 diabetes found probiotics improve fasting blood sugar, HbA1c, insulin levels, and insulin resistance. The effects are small but consistent. In clinical terms, HbA1c dropped by about 0.19% and fasting glucose by about 1.0 mmol/L. Bifidobacterium strains and food-based probiotics (like yogurt) worked best. People with higher BMI got more benefit.
The effect sizes are statistically significant but clinically modest. HbA1c -0.19% is below the 0.5% threshold most doctors consider meaningful. FBG -1.0 mmol/L is marginally clinically relevant. HOMA-IR had the highest GRADE certainty (High). No publication bias was detected. Low heterogeneity for FBG (I2=29%) is encouraging. This won't replace diabetes medication, but it appears to be a safe adjunct therapy.
View full statistical analysis
Publication Bias Assessment
| Egger's Test | z = —, p = 0.349 | no publication bias detected for any glycemic outcome |
|---|
Subgroup Analysis
| Subgroup | Studies (k) | Effect (g) |
|---|---|---|
| Bifidobacterium | 2 | -0.626 |
| Lactobacillus + Bifidobacterium | 14 | -0.341 |
| Lactobacillus | 11 | -0.259 |
| Subgroup | Studies (k) | Effect (g) |
|---|---|---|
| BMI >= 30 | 13 | -0.49 |
| BMI < 30 | 17 | -0.228 |
| Subgroup | Studies (k) | Effect (g) |
|---|---|---|
| Food-type (yogurt, fermented milk) | 8 | -0.524 |
| Non-food (capsule, tablet, powder) | 15 | -0.322 |
Dosage Guide
| Dose Range in Studies | 1-100 billion CFU (strain-dependent) |
|---|---|
| Most-Studied Dose | 10-20 billion CFU multi-strain |
| Best Form | Strain-specific capsules or sachets |
| Timing | With or without food (strain-dependent, check label) |
| Time to Effect | 2-4 weeks for gut symptoms, 4-8 weeks for mood |
| Cycling | No cycling needed. Consistent daily use recommended. |
| Notes | Strain specificity matters enormously. L. plantarum 299V for IBS. Lactobacillus and Bifidobacterium blends for immune support. Refrigerated products may maintain potency better, but shelf-stable formulations with proper packaging also work. |
Ask Your Doctor Before Taking If You Have
- Severely immunocompromised patients (risk of bacteremia)
- Short bowel syndrome
- Central venous catheters (rare infection risk)
Drug Interactions
| Medication | Risk | Why |
|---|---|---|
| Immunosuppressants | moderate | Live bacteria could pose infection risk in immunocompromised patients. Consult doctor before use. |
| Antibiotics | low | Antibiotics may kill probiotic bacteria. Take probiotics 2-3 hours apart from antibiotics. |
Possible Side Effects
- Mild gas and bloating in the first few days
- Rare: headaches during initial adjustment
Products That Match the Research
Disclosure: Links below are affiliate links. We earn a commission if you buy. We only link to products that match the doses and forms used in the published research.
Seed DS-01 Daily Synbiotic
24-strain synbiotic with 53.6 billion AFU, triple-encapsulated for survival past stomach acid, prebiotic included
What to Avoid
Most grocery store probiotics don't list specific strains, have low CFU counts, and lack third-party testing for viability
Frequently Asked Questions
Do probiotics actually work for IBS?
Yes. Two large meta-analyses (72 and 82 RCTs) found probiotics significantly improve global IBS symptoms, abdominal pain, and quality of life. L. plantarum 299V and Bacillus strains had the strongest evidence. The effect is moderate but consistent across studies.
Which probiotic strain is best?
It depends on your goal. For IBS and abdominal pain, Bacillus strains and L. plantarum 299V have the best data. For immune support, Lactobacillus and Bifidobacterium blends are most studied. For mood, multi-strain formulations showed the largest effects. Don't just grab a random bottle.
How many billion CFU do I need?
There's no magic number. Most studies used 1-100 billion CFU. The strain matters more than the count. A well-studied strain at 10 billion CFU will outperform a random strain at 100 billion. Look for specific strain codes (like L. plantarum 299V), not just high CFU numbers.
Are probiotics safe for everyone?
For most healthy adults, yes. Probiotics are very safe. The main exception is people with severely weakened immune systems (organ transplant recipients, late-stage HIV, chemotherapy patients). If you're immunocompromised, talk to your doctor first. Mild gas or bloating in the first few days is normal.
Should I refrigerate my probiotics?
It depends on the product. Some strains need refrigeration to stay alive. Others are shelf-stable with proper packaging. Check the label. Shelf-stable products with good encapsulation technology (like enteric coating or triple encapsulation) can work just as well as refrigerated ones.
Want to see the data? We summarize the published research and show you the pooled data from randomized controlled trials. Read our full methodology and dataset below
Summary
Based on our systematic summary of 7 health claims across 306 studies with 52,179 total participants, 4 claims have strong evidence supporting them, 3 claims show promising but incomplete evidence. Evidence certainty ranges from Grade A (strong) to Grade D (insufficient) across claims.
Summary of Findings
| Outcome | Studies | Participants | Effect Size (95% CI) | Certainty |
|---|---|---|---|---|
| Improves IBS and gut health | 72 | 8,581 | SMD -0.55 (-0.76 to -0.34) | Grade A |
| Reduces respiratory infections | 24 | 6,950 | RR 0.76 (0.67 to 0.87) | Grade B |
| Improves mood and depression | 23 | 1,401 | SMD -0.96 (-1.31 to -0.61) | Grade B |
| Prevents antibiotic-associated diarrhea | 42 | 11,305 | RR 0.63 (0.54 to 0.73) | Grade A |
| Prevents C. difficile-associated diarrhea | 31 | 8,672 | RR 0.4 (0.3 to 0.52) | Grade A |
| Reduces diarrhea duration in acute gastroenteritis | 84 | 13,443 | MD -1.25 (-1.59 to -0.91) | Grade B |
| Improves blood sugar control in type 2 diabetes | 30 | 1,827 | SMD -0.331 (-0.424 to -0.238) | Grade B |
Review Protocol
For each claim, we searched for the most recent published systematic review or meta-analysis of randomized controlled trials evaluating probiotics supplementation in human participants compared to placebo or no treatment.
When a full protocol file is available, it can be found at /supplements/probiotics/protocol/.
Search Strategy
Databases searched: PubMed, Cochrane, Google Scholar
Last searched: 2026-02-20T23:00:00Z
Studies reviewed: 320
Studies meeting inclusion criteria: 259
Searches targeted published systematic reviews and meta-analyses of RCTs for each health claim. Individual RCTs were included when no pooled analysis existed.
Study Selection
Each claim was evaluated independently. The PRISMA flow below summarizes the selection process per outcome.
| Claim | Identified | Screened | Excluded | Included |
|---|---|---|---|---|
| Improves IBS and gut health | 4200 | 1850 | 1640 | 72 |
| Reduces respiratory infections | 3800 | 1200 | 1100 | 24 |
| Improves mood and depression | 2100 | 840 | 760 | 23 |
| Prevents antibiotic-associated diarrhea | 356 | 250 | 190 | 42 |
| Prevents C. difficile-associated diarrhea | ||||
| Reduces diarrhea duration in acute gastroenteritis | 3927 | 528 | 84 | |
| Improves blood sugar control in type 2 diabetes | 4049 | 2924 | 2821 | 30 |
Risk of Bias
Assessment tool: Cochrane RoB 2 for RCTs, ROBINS-I for non-randomized studies.
Individual study risk-of-bias assessments are summarized below by claim. Full per-domain assessments will be available in the downloadable study ledger when published.
| Claim | Studies | Low RoB | Some Concerns | High RoB |
|---|---|---|---|---|
| Improves IBS and gut health | 72 | 1 | 0 | 0 |
| Reduces respiratory infections | 24 | 0 | 0 | 0 |
| Improves mood and depression | 23 | 0 | 0 | 0 |
| Prevents antibiotic-associated diarrhea | 42 | 2 | 6 | 0 |
| Prevents C. difficile-associated diarrhea | 31 | 2 | 4 | 0 |
| Reduces diarrhea duration in acute gastroenteritis | 84 | 3 | 4 | 1 |
| Improves blood sugar control in type 2 diabetes | 30 | 2 | 6 | 0 |
Results
Improves IBS and gut health
Pooled effect: SMD = -0.55 (95% CI: -0.76 to -0.34, p = 0.001)
Heterogeneity: I² = 96.3%, τ² = 0.45, Cochran's Q = 1920
72 studies with over 8,500 people found probiotics significantly improve IBS symptoms. The effect is moderate. Abdominal pain improves the most, especially with Bacillus strains. Quality of life also gets a meaningful boost.
Reduces respiratory infections
Pooled effect: RR = 0.76 (95% CI: 0.67 to 0.87, p = 0.001)
Heterogeneity: I² = 71%, τ² = 0.04, Cochran's Q = 79.3
A Cochrane review of 24 studies with nearly 7,000 people found probiotics reduce your chance of getting at least one upper respiratory infection by about 24%. People who took probiotics were also 41% less likely to get 3 or more infections. Colds were about 1.2 days shorter.
Improves mood and depression
Pooled effect: SMD = -0.96 (95% CI: -1.31 to -0.61, p = 0.001)
Heterogeneity: I² = 85%, τ² = 0.38, Cochran's Q = 146.7
23 studies with about 1,400 people found a large effect of probiotics on depression scores. Anxiety scores also improved. The effect was bigger in people with clinical depression compared to healthy volunteers. Shorter trials showed larger effects, which raises some questions about durability.
Prevents antibiotic-associated diarrhea
Pooled effect: RR = 0.63 (95% CI: 0.54 to 0.73, p = 1e-05)
Heterogeneity: I² = 60%, τ² =
42 studies with over 11,000 adults found probiotics reduce your risk of getting diarrhea from antibiotics by 37%. The benefit is strongest in people who are already at high risk for this side effect. You'd need to treat about 20 patients to prevent one case. Lactobacillus and Bifidobacterium strains are the most effective.
Prevents C. difficile-associated diarrhea
Pooled effect: RR = 0.4 (95% CI: 0.3 to 0.52, p = 1e-05)
Heterogeneity: I² = %, τ² =
A Cochrane review of 31 trials with 8,672 people found probiotics cut the risk of C. difficile diarrhea by 60%. The incidence dropped from 4.0% in the control group to 1.5% in the probiotic group. In high-risk patients (baseline risk over 5%), the reduction was even bigger at 70%, with a number needed to treat of just 12.
Reduces diarrhea duration in acute gastroenteritis
Pooled effect: MD = -1.25 (95% CI: -1.59 to -0.91, p = 0.05)
Heterogeneity: I² = %, τ² =
The evidence here is conflicting. A network meta-analysis of 84 studies with 13,443 children found S. boulardii shortens diarrhea by about 1.25 days. But a 2020 Cochrane review of 82 studies found no benefit when they only looked at the highest-quality trials. Two large, well-designed NEJM trials (nearly 1,800 children combined) found zero benefit from L. rhamnosus GG.
Improves blood sugar control in type 2 diabetes
Pooled effect: SMD = -0.331 (95% CI: -0.424 to -0.238, p = 0.001)
Heterogeneity: I² = 29%, τ² =
30 studies with 1,827 people with type 2 diabetes found probiotics improve fasting blood sugar, HbA1c, insulin levels, and insulin resistance. The effects are small but consistent. In clinical terms, HbA1c dropped by about 0.19% and fasting glucose by about 1.0 mmol/L. Bifidobacterium strains and food-based probiotics (like yogurt) worked best. People with higher BMI got more benefit.
Sensitivity Analysis
Prediction intervals indicate the range of effects expected in a new study. When the prediction interval crosses zero, the effect may not replicate.
| Claim | Effect | 95% PI | Crosses Zero? |
|---|---|---|---|
| Improves IBS and gut health | -0.55 | -1.87 to 0.77 | Yes |
| Reduces respiratory infections | 0.76 | 0.48 to 1.2 | No |
| Improves mood and depression | -0.96 | -2.18 to 0.26 | Yes |
Publication Bias
Funnel plots and Egger's regression test were used to assess publication bias where 10 or more studies were available.
| Claim | Egger's p | Interpretation | Trim-and-Fill Estimate |
|---|---|---|---|
| Improves IBS and gut health | 0.08 | some asymmetry detected but not statistically significant | — |
| Reduces respiratory infections | — | not formally assessed in Cochrane review | — |
| Improves mood and depression | — | potential asymmetry, insufficient studies for robust testing | — |
| Prevents antibiotic-associated diarrhea | — | funnel plot symmetrical, suggesting little evidence of publication bias | — |
| Prevents C. difficile-associated diarrhea | — | not formally tested, but sensitivity analyses robust to missing data assumptions | — |
| Reduces diarrhea duration in acute gastroenteritis | 0.002 | publication bias demonstrated in Cochrane review, funnel plots clearly asymmetric | — |
| Improves blood sugar control in type 2 diabetes | 0.349 | no publication bias detected for any glycemic outcome | — |
Certainty of Evidence
Evidence grades follow a simplified GRADE framework: A (high certainty), B (moderate), C (low), D (very low/insufficient).
| Outcome | Grade | Verdict | Key Limitation |
|---|---|---|---|
| Improves IBS and gut health | A | works | Very high heterogeneity (I2 = 96.3%) is the big caveat. Different strains, doses, and populations produce wildly … |
| Reduces respiratory infections | B | works | This is a Cochrane review, which is the gold standard. But certainty was rated Low for most outcomes because of high … |
| Improves mood and depression | B | maybe | The effect size (SMD -0.96) looks impressive, but I2 = 85% means results vary a lot between studies. The prediction … |
| Prevents antibiotic-associated diarrhea | A | works | GRADE quality is Moderate. Three independent meta-analyses (Goodman 2021, Liao 2021, Hempel 2012) all found consistent … |
| Prevents C. difficile-associated diarrhea | A | works | This is Cochrane-quality evidence rated Moderate certainty. The 60% risk reduction is dramatic. But it only applies to … |
| Reduces diarrhea duration in acute gastroenteritis | B | maybe | This claim gets a 'maybe' because the evidence is genuinely split. Multiple meta-analyses find a benefit (Li 2021 NMA, … |
| Improves blood sugar control in type 2 diabetes | B | maybe | The effect sizes are statistically significant but clinically modest. HbA1c -0.19% is below the 0.5% threshold most … |
Limitations
- Searches were limited to English-language publications. Non-English studies may be missing.
- Study identification and data extraction were assisted by AI tools. All extracted data has been manually verified against source publications.
- Small-study effects may inflate some pooled estimates, particularly for outcomes with fewer than 10 included trials.
- Supplement formulations, dosages, and populations varied across studies. Subgroup analyses were limited by the number of available studies per subgroup.
- Most included studies relied on published meta-analyses as the primary data source. Individual participant data was not available.
Conflicts of Interest & Disclosures
SnakeOilCheck earns commissions from qualifying purchases made through affiliate links on this site. Our meta-analyses are produced independently and are not influenced by affiliate relationships.
All claims are sourced from PubMed-indexed meta-analyses and RCTs. Every assertion includes a specific citation with PMID for independent verification.
AI-assisted research disclosure: Study identification and data extraction were assisted by AI tools. All extracted data has been manually verified against source publications.
Raw Data
Downloadable study ledger files (CSV, JSON) and verification logs will be published as we complete the transition to our new data format. In the meantime, all source meta-analyses are cited in the claim sections above with DOIs for independent verification.
License: CC BY 4.0
How to Cite
SnakeOilCheck. Probiotics: Systematic Review and Meta-Analysis. snakeoilcheck.com/supplements/probiotics/. Updated 2026-02-20 00:00:00 +0000 UTC.